Latest Regulatory Progress News

Page 1 of 58
Palo Alto Networks delivered a strong fiscal first quarter and materially raised its full-year outlook while agreeing to acquire Applied Compute for US$4.5 billion in stock. The deal would add open-weight AI model capabilities, but its value, dilution and integration risks remain unresolved.
Sophie Babbage
Sophie Babbage
19 Nov 2026
Smart Parking has posted record FY26 revenue of $126.0 million and adjusted EBITDA of $30.8 million, while setting a target of 3,000 ANPR sites by December 2028. The next phase will require the company to turn US investment, acquisitions and regulatory progress into sustained site growth.
Victor Sage
Victor Sage
13 Nov 2026
Nanosonics has secured a second US FDA 510(k) clearance for its CORIS System, expanding the range of colonoscopes and gastroscopes eligible for reprocessing. The regulatory milestone supports planned US launch activities, although the company has not disclosed a launch date or financial forecast.
Ada Torres
Ada Torres
11 Nov 2026
BTC Health has expanded its exclusive ExoVasc PEARS distribution rights from Australia into India under a new five-year agreement. The opportunity is potentially significant, but Indian sales remain dependent on CDSCO import approval.
Ada Torres
Ada Torres
6 Nov 2026
Vita Resources has submitted a revised application seeking consent for lower-impact exploration at its ICE Polymetallic Project in Yukon during the 2027 field season. The work could sharpen targets for future drilling, but Ross River Dena Council approval and funding remain outstanding.
Maxwell Dee
Maxwell Dee
6 Nov 2026
Rua Gold has submitted the substantive fast-track application for its proposed underground Auld Creek gold-antimony mine in New Zealand’s Reefton Goldfield. The milestone moves the project into statutory review, but it is not an approval and the company’s mid-2027 permitting target remains conditional.
Maxwell Dee
Maxwell Dee
6 Nov 2026
Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.
Ada Torres
Ada Torres
5 Nov 2026
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Whitehaven Coal’s Winchester South project has received a recommendation for approval from the Queensland Land Court, advancing a key regulatory process. Final Queensland decisions and Commonwealth environmental approval are still required before the project can proceed.
Maxwell Dee
Maxwell Dee
2 Nov 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
LCL Resources has added a second Rio Tinto-funded exploration program in Papua New Guinea, while completing a 5,598 line-kilometre survey at its Ono project. The deal could see Rio Tinto earn up to 80% of Liamu, leaving LCL with funded exposure to several undrilled targets and A$7.76 million in cash.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive